Citadel Advisors
BDTX icon

Citadel Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Citadel Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-502,652
Closed -$1.23M – 13699
2026
Q1 		$1.07M Buy
502,652
+77,193
+18% +$184K ﹤0.01% 7500
2025
Q4 		$1.03M Buy
+425,459
New +$1.51M ﹤0.01% 7326
2025
Q3 		– Sell
-185,272
Closed -$459K – 12766
2025
Q2 		$459K Buy
+185,272
New +$357K ﹤0.01% 8836
2024
Q4 		– Sell
-703,704
Closed -$2.02M – 14499
2024
Q3 		$3.06M Buy
703,704
+699,175
+15,438% +$3.8M ﹤0.01% 4744
2024
Q2 		$21.1K Sell
4,529
-6,557
-59% -$35.2K ﹤0.01% 12587
2024
Q1 		$56.2K Sell
11,086
-109,679
-91% -$442K ﹤0.01% 12063
2023
Q4 		$339K Buy
120,765
+101,994
+543% +$239K ﹤0.01% 8919
2023
Q3 		$53.9K Sell
18,771
-1,196,637
-98% -$4.41M ﹤0.01% 11677
2023
Q2 		$6.14M Buy
1,215,408
+657,637
+118% +$1.34M ﹤0.01% 3330
2023
Q1 		$1.05M Sell
557,771
-216,027
-28% -$496K ﹤0.01% 6662
2022
Q4 		$1.39M Buy
773,798
+733,149
+1,804% +$1.32M ﹤0.01% 6184
2022
Q3 		$69K Sell
40,649
-45,295
-53% -$140K ﹤0.01% 11399
2022
Q2 		$211K Buy
85,944
+42,856
+99% +$99.6K ﹤0.01% 10588
2022
Q1 		$119K Buy
43,088
+491
+1% +$1.79K ﹤0.01% 12092
2021
Q4 		$227K Buy
42,597
+971
+2% +$6.78K ﹤0.01% 11585
2021
Q3 		$352K Buy
41,626
+11,445
+38% +$113K ﹤0.01% 10706
2021
Q2 		$368K Buy
30,181
+13,062
+76% +$258K ﹤0.01% 10769
2021
Q1 		$415K Buy
+17,119
New +$462K ﹤0.01% 10084

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors's BDTX Position: Q2 2026 in Review

Citadel Advisors sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 502,652 shares — an estimated $1.23M sold.

Citadel Advisors first reported a position in BDTX in Q1 2021 and held it in 18 quarters. The position peaked at $6.14M in Q2 2023. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Citadel Advisors reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 502,652 Black Diamond Therapeutics shares in Q2 2026, an estimated $1.23M.
  • Citadel Advisors first reported a position in Black Diamond Therapeutics in Q1 2021 and held it in 18 quarters.
  • Citadel Advisors's Black Diamond Therapeutics position peaked at $6.14M in Q2 2023.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.